Get the Stockscreener App
438.34
2.20%
-9.87
Overview
News
Price History
Option Chain
Financials
Why TMO Down?
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc stock is traded at $438.34, with a volume of 2.04M.
It is down -2.20% in the last 24 hours and down -17.55% over the past month.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
See More
Previous Close:
$448.21
Open:
$444.02
24h Volume:
2.04M
Relative Volume:
0.93
Market Cap:
$162.90B
Revenue:
$45.20B
Net Income/Loss:
$6.87B
P/E Ratio:
24.10
EPS:
18.1888
Net Cash Flow:
$6.75B
1W Performance:
-5.73%
1M Performance:
-17.55%
6M Performance:
-24.26%
1Y Performance:
+8.25%
1-Day Range:
$437.32
$444.95
1-Week Range:
$437.32
$466.79
52-Week Range:
$385.46
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc
Sector
Industry
Phone
(781) 622-1000
Address
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | DZ Bank | Buy |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Dec-09-25 | Initiated | Goldman | Buy |
| Dec-08-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Dec-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-11-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-19-25 | Initiated | William Blair | Outperform |
| Jul-24-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jul-09-25 | Downgrade | UBS | Buy → Neutral |
| Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Mar-18-24 | Resumed | Citigroup | Neutral |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-06-23 | Resumed | Citigroup | Buy |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
| Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-04-23 | Reiterated | Barclays | Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-26-22 | Resumed | Barclays | Overweight |
| Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-14-20 | Initiated | Morgan Stanley | Overweight |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
| Jul-07-20 | Reiterated | Needham | Buy |
| Apr-23-20 | Reiterated | Needham | Buy |
| Jan-31-20 | Reiterated | Needham | Buy |
| Jan-22-20 | Initiated | Credit Suisse | Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-25-19 | Reiterated | Needham | Buy |
| Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| May-23-19 | Reiterated | Needham | Strong Buy |
| Apr-22-19 | Reiterated | Needham | Strong Buy |
| Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc Stock (TMO) Latest News
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know - Yahoo Finance
Thermo Fisher Scientific (TMO) Reports Strong Q1 FY2026 Earnings - GuruFocus
Is Thermo Fisher (TMO) Quietly Reinforcing Its End‑to‑End Biopharma Role With New IBTROZI Duties? - simplywall.st
Thermo Fisher Scientific Inc. stock falls Friday, underperforms market - MarketWatch
Thermo Fisher (TMO) Coverage Resumed with Sector Perform Rating - GuruFocus
RBC Capital assumes Thermo Fisher stock with Sector Perform rating - Investing.com
RBC Capital assumes Thermo Fisher stock with Sector Perform rating By Investing.com - Investing.com Canada
Ex-Investor Seeks Records On $8.9B Thermo Fisher Payout - Law360
Thermo Fisher Scientific stock (US8835561023): Q1 earnings beat with EPS of $5.44 - AD HOC NEWS
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
Nuvation Bio Completes IBTROZI Manufacturing Tech Transfer to Thermo Fisher - Contract Pharma
Bioinformatics Platforms Market Is Going to Boom | • Illumina Inc • Thermo Fisher Scientific Inc • QIAGEN N.V - openPR.com
Nuvation Bio stock (US55043Q1004): Manufacturing deal with Thermo Fisher for lung cancer drug - AD HOC NEWS
Cell Cryopreservation Market 2026- 2033 Overview: Share, Size, - openPR.com
Thermo Fisher Scientific stock (US8835561023): Q1 earnings beat signals strength in life sciences - AD HOC NEWS
Can Mettler-Toledo International Outrun Thermo Fisher Scientific in the Next Rally? - Trefis
Between Mettler-Toledo International and Thermo Fisher Scientific, Which Stock Looks Set to Break Out? - Trefis
Thermo Fisher (TMO) Completes Tech Transfer for Ibtrozi - GuruFocus
Nuvation Bio Collaborates With Thermo Fisher Scientific For Lung Cancer Treatment - Moomoo
Thermo Fisher Scientific Inc. stock falls Wednesday, underperforms market - MarketWatch
Nuvation Bio partners with Thermo Fisher for US drug manufacturing - Investing.com
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer - Yahoo Finance
Thermo Fisher Sci. stock (US8835561023): Recent earnings beat and price gain - AD HOC NEWS
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market - MarketWatch
Thermo Fisher Sci. stock (US8835561023): Leader in life sciences tools - AD HOC NEWS
Nucleic Acid Isolation and Purification Market Report 2026-2030: Trends, Challenges and Competitive Analysis Featuring Thermo Fisher Scientific, Merck, QIAGEN, and Roche - Yahoo Finance
Westpac Banking Corp's Thermo Fisher Scientific Inc(TMO) Holding History - GuruFocus
Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S Cash Flow – TSX:TMO - TradingView
Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S - TradingView
Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S Balance Sheet – TSX:TMO - TradingView
Thermo Fisher Scientific Inc. stock falls Monday, underperforms market - MarketWatch
Thermo Fisher Expands Cell Therapy And Hydration Platforms To Deepen Ecosystem - Yahoo Finance
Thermo Fisher Scientific : Additional Soliciting Materials - marketscreener.com
Thermo Fisher Sci. stock (US8835561023): Q1 2026 earnings beat estimates - AD HOC NEWS
Upstream Bioprocessing Equipment Market Is Going to Boom | Thermo Fisher Scientific, Merck KGaA, Sartorius AG - openPR.com
Thermo Fisher Scientific Inc (TMO): An Investor Outlook with Strong Buy Ratings and Robust Revenue Growth - DirectorsTalk Interviews
Cross-Belt Analyzers Market Size Accelerating at 8.7% CAGR | - openPR.com
Thermo Fisher Scientific acquires Clario for nearly $8.9bn - MSN
Thermo Fisher Sci. stock (US8835561023): Earnings beat and guidance lift drive shares higher - AD HOC NEWS
Jim Cramer on Thermo Fisher: “I Think You Can Buy It at This Level” - Yahoo Finance
Wall Street Zen Downgrades Thermo Fisher Scientific (NYSE:TMO) to Hold - MarketBeat
Wells Fargo Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Cuts Target Price to $615 - Moomoo
Thermo Fisher Scientific Launches PackEye™ XS Radiation Detection Backpack: Covert, High-Accuracy Identification in a Lightweight, Mission-Ready Design - AZoSensors
Polystyrene Latex Particle Market Size Advancing at 6.3% CAGR | - openPR.com
Morgan Stanley, Thermo Fisher, Blue Owl Technology Finance and more on CNBC's 'Final Trades' - MSN
Is It Time To Revisit Thermo Fisher Scientific (TMO) After This Year’s Share Price Pullback - Yahoo Finance
Thermo Fisher Scientific Inc. stock rises Wednesday, still underperforms market - MarketWatch
Thermo Fisher Scientific’s Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider - PharmiWeb.com
Thermo Fisher Scientific’s Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider Lens™ Report for Use of AI in Clinical Trials - BioSpace
Thermo Fisher projects 2026 adjusted EPS of $24.64-$25.12 as it raises revenue outlook to $47.3B-$48.1B - MSN
Erste Group Maintains Thermo Fisher Scientific(TMO.US) With Hold Rating - Moomoo
Thermo Fisher Scientific Inc Stock (TMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):